|Bid||11.90 x 200|
|Ask||12.22 x 500|
|Day's Range||12.07 - 12.58|
|52 Week Range||2.84 - 13.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The volatile nature of biotech stocks is evident from the wild swings they experience in the wake of catalytic events, which in fact present profit-making opportunities for an astute investor. This week ...
ImmunoGen (IMGN) advances with lead ovarian cancer candidate, mirvetuximab soravtansine. Moreover, combo therapies with the candidate for the indication are underway.
ImmunoGen (IMGN) reports wider-than-expected loss in Q4. However, higher license and milestone fees drive substantial revenue rise year over year.
In this article I am going to calculate the intrinsic value of ImmunoGen Inc (NASDAQ:IMGN) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs, came to 10 cents per share. The results missed Wall Street expectations. ...
ImmunoGen (IMGN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.
ImmunoGen (IMGN) begins a phase I study to evaluate its anti-CD123 antibody-drug conjugates, IMGN632, for treating patients with hematological malignancies.